Trial Profile
An Observational, Prospective, Cohort Study to Evaluate Safety and Efficacy of Remsima in Patients With Ankylosing Spondylitis
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 21 Jul 2021
Price :
$35
*
At a glance
- Drugs Infliximab (Primary) ; Adalimumab; Etanercept
- Indications Ankylosing spondylitis
- Focus Adverse reactions
- Sponsors Celltrion
- 12 Jul 2021 Results of a pooled analysis assessing long-term safety and effectiveness over 5 years from three observational studies: NCT02557295, NCT02326155 and NCT02557308 published in the Advances in Therapy
- 30 Apr 2020 Results of post marketing pooled analysis of six observational studies published in the BioDrugs
- 15 Jun 2019 Results assessing pooled analysis of this and other three global post-marketing studies (KOREA PMS, CT-P13 4.2, and PERSIST) presented at the 20th Annual Congress of the European League Against Rheumatism